Endocrine Abstracts

Weight loss is a common symptom observed in the majority of patients presenting with autoimmune Graves’ hyperthyroidism. The three main treatment modalities used for treatment of Graves’ disease are associated with excess weight gain, reportedly over and above regain of lost weight. Hyperthyroidism is associated with alterations in satiety signals and there are conflicting data relating to whether lean or fat mass are increased following successful treatment. Risk factors for excessive weight gain include pre-existing obesity and more severe hyperthyroidism. Some studies indicate that weight gain is more pronounced with treatments that are associated with the induction of hypothyroidism namely the administration of radioactive iodine and surgery. Since the induction of hypothyroidism has been associated with reduced risks of mortality in patients with Graves’ disease, this may a desirable outcome, although patients remain worried regarding the risk of gaining weight. Preliminary data indicate that dietary interventions may be useful in preventing excessive weight gain but no large randomised trials have been undertaken to indicate beneficial effects of lifestyle changes. This symposium will highlight the current evidence with regards to weight changes associated with Graves’ disease and its treatment, explore the underlying mechanisms and provide an overview of potential therapeutic avenues that may be beneficial.